Correspondence | Published:

Challenges in the gene therapy commercial ecosystem

Nature Biotechnology volume 35, pages 813815 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Nat. Rev. Genet. 4, 346–358 (2003).

  2. 2.

    , , & Nat. Biotechnol. 23, 1073–1078 (2005).

  3. 3.

    Hum. Gene Ther. 23, 1–3 (2012).

  4. 4.

    & Acad. Manage. J. 58, 1180–1207 (2015).

  5. 5.

    & Nat. Biotechnol. 32, 874–876 (2014).

Download references

Author information

Affiliations

  1. The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • Rahul Kapoor
  2. IESE Business School, Barcelona, Spain.

    • Thomas Klueter
  3. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • James M Wilson

Authors

  1. Search for Rahul Kapoor in:

  2. Search for Thomas Klueter in:

  3. Search for James M Wilson in:

Competing interests

J.M.W. is an advisor to REGENXBIO, Dimension Therapeutics and Solid Gene Therapy, and is a founder of, holds equity in, and has a sponsored research agreement with REGENXBIO and Dimension Therapeutics. In addition, he is a consultant to several biopharmaceutical companies and is an inventor on patents licensed to various biopharmaceutical companies.

Corresponding author

Correspondence to Rahul Kapoor.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.3931

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing